Valdecoxib

Reviews in Gastroenterological Disorders

Volumn 2, Issue 3, 2002, Pages 116-125

  Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Bextra; Dysmenorrhea; Osteoarthritis; Rheumatoid arthritis; Selective COX 2 inhibitor; Valdecoxib

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRHEUMATIC AGENT; CELECOXIB; CORTICOSTEROID; CROSCARMELLOSE SODIUM; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DICLOFENAC; FLUCONAZOLE; GLUCURONIDE; GOLD SALT; HYDROXYCHLOROQUINE; HYDROXYPROPYLMETHYLCELLULOSE; IBUPROFEN; ISOENZYME; KETOCONAZOLE; LACTOSE; MAGNESIUM STEARATE; METHOTREXATE; MICROCRYSTALLINE CELLULOSE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POLYSORBATE 80; PROPYLENE GLYCOL; ROFECOXIB; UNINDEXED DRUG; VALDECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG SELECTIVITY; DYSMENORRHEA; FOOD DRUG INTERACTION; GASTROINTESTINAL TOXICITY; HUMAN; NONHUMAN; OSTEOARTHRITIS; PAIN; REVIEW; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2; ENZYME INHIBITORS; HUMANS; ISOENZYMES; ISOXAZOLES; MEMBRANE PROTEINS; OSTEOARTHRITIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONAMIDES;

EID: 0036592553     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2
2. A double-blind, placebo-controlled study to evaluate the effects of valdecoxib, a novel COX-2 specific inhibitor, on platelet function in the elderly
3. The novel COX-2 specific inhibitor, valdecoxib, does not affect platelet function in healthy males
4. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin
5. Cyclooxygenase-2 specific inhibitor valdecoxib: Single and multiple dose pharmacokinetic profile in healthy adults
6. A double-blind, placebo-controlled dose ranging study to evaluate the efficacy of valdecoxib, a novel COX-2 specific inhibitor, in treating the signs and symptoms of osteoarthritis of the knee
7. The COX-2 specific inhibitor valdecoxib is effective in treating symptomatic osteoarthritis of the hip
8. The COX-2 specific inhibitor valdecoxib is as effective as the conventional NSAID naproxen in treating symptomatic osteoarthritis of the knee and demonstrates reduced gastrointestinal ulceration
9. Valdecoxib, a new COX-2 specific inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis
10. The cyclooxygenase (COX)-2 specific inhibitor valdecoxib effectively treats primary dysmenorrhea
11. Reduced incidence of gastroduodenal ulcers with valdecoxib compared to ibuprofen and diclofenac in patients with osteoarthritis: A multicenter study
12. Supratherapeutic doses of valdecoxib have a reduced incidence of gastroduodenal ulcers compared with conventional therapeutic doses of naproxen in osteoarthritis and rheumatoid arthritis patients
13. Comparative gastroduodenal mucosal effects of valdecoxib, a potent COX-2 specific inhibitor, compared with naproxen and placebo